US approval for Novartis' Afinitor in pancreatic NETs
This article was originally published in Scrip
Executive Summary
The US FDA approved Novartis' Afinitor (everolimus), making it the first new treatment in nearly three decades for patients with a rare type of cancer, known as pancreatic neuroendocrine tumours (NETs).